Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study - 01/09/11
Abstract |
Recalcitrant pruritus is a hallmark of lichen simplex, a localized variant of atopic dermatitis. Acetylcholine has been demonstrated to mediate pruritus in atopic dermatitis. This open pilot study was done to determine the therapeutic effect of blocking acetylcholine release with botulinum toxin A in highly pruritic lichen simplex. Botulinum toxin A (Dysport) was injected intradermally into 5 circumscribed lichenoid lesions in 3 patients suffering from recalcitrant pruritus. No corticosteroids or any other specific topical therapy was administered. Pruritus subsided within 3 to 7 days in all 3 patients. Within 2 to 4 weeks all lesions cleared completely. No recurrences were noted over a 4-month follow-up. In one patient lichen simplex developed on the contralateral shin, which responded equally to a subsequent injection. We concluded that lichen simplex-associated pruritus can be overcome by intradermal botulinum toxin A injection. Acetylcholine appears to be a dominant pruritic mediator in this condition. (J Am Acad Dermatol 2002;46:617-9.)
Le texte complet de cet article est disponible en PDF.Plan
Funding: None. |
|
Disclosure: Dr Heckmann has received honoraria from companies that manufacture botulinum A toxin (Ipsen-Pharma, Beaufort, France, and Allergan, Irvine, Calif) for speeches given at clinical symposia. |
|
Reprints not available from authors. |
|
Published online January 11, 2002. |
Vol 46 - N° 4
P. 617-619 - avril 2002 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?